Human immunodeficiency virus and liver disease: An update

Hepatology

Volumn 62, Issue 6, 2015, Pages 1871-1882

  Sherman, Kenneth E ^a   Rockstroh, Juergen ^b   Thomas, David ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; DRUG INTERACTION; END STAGE LIVER DISEASE; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS C; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; LIVER CELL CARCINOMA; LIVER DISEASE; MIXED INFECTION; PATHOGENESIS; PRIORITY JOURNAL; SOCIAL PSYCHOLOGY; COMPLICATION; IMMUNOLOGY; LIVER DISEASES; UNITED STATES; VIROLOGY;

HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES; UNITED STATES;

EID: 84955202684     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28150     Document Type: Article

References (80)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival in patients with HIV infection. [in Danish] Ugeskr Laeger 2007;169:2529-2532.
2. + cell count and viral load response to antiretroviral therapy. AIDS 2014;28:1193-202.
3. Cohen SM, Van Handel MM, Branson BM, et al. Vital signs: HIV prevention through care and treatment-United States. JAMA 2012;307:247-250. Reprinted from MMWR 2011;60:1618-1623.
4. Hall HI, Walker F, Shah D, Belle E. Trends in HIV diagnoses and testing among U.S. adolescents and young adults. AIDS Behav 2012;16:36-43.
5. Brecher ME, Hay SN, Park YA. Is it HIV TTP or HIV-associated thrombotic microangiopathy? J Clin Apher 2008;23:186-190.
6. Goedert JJ; Second Multicenter Hemophilia Cohort Study. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. Haemophilia 2005;11:516-528.
7. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007;102:2536-2540.
8. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Mispo ME, Martin-Carbonero L, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008;13:103-107.
9. Shire NJ, Rao MB, Succop P, Buncher CR, Andersen JA, Butt AA, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2009;7:471-480.
10. Berenguer J, Zamora FX, Aldamiz-Echevarria T, Von Wichmann MA, Crespo M, López-Aldeguer J, et al. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2015;60:950-958.
11. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-12676.
12. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-1739.
13. Rodriguez JM, Hermida JM, Casado JL, Quereda C, Moreno A, Dronda F, et al. The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. AIDS 2011;25:1006-1009.
14. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-1641.
15. Kamar N, Izopet J, Rostaing L. Hepatitis E virus infection. Curr Opin Gastroenterol 2013;29:271-278.
16. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Bagai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in northern California. J Gastroenterol Hepatol 2013;28:1521-1525.
17. Razeghi SR, Sherman KE. Prevalence of HDV in a Midwestern HIV-HBV coinfected population [Abstract]. In: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Abstract 707.
18. Muhula SO, Peter M, Sibhatu B, Meshack N, Lennie K. Effects of highly active antiretroviral therapy on the survival of HIV-infected adult patients in urban slums of Kenya. Pan Afr Med J 2015;20:63.
19. Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005;10:779-790.
20. Macias J, Gonzalez J, Tural C, Ortega-González E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 2014;28:1279-1287.
21. Ryan P, Berenguer J, Michelaud D, Miralles P, Bellón JM, Alvarez E, et al. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009;50:109-110.
22. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009;50:464-473.
23. Macias J, Berenguer J, Japon MA, Girón-González JA, Rivero A, López-Cortés LF, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012;56:1261-1270.
24. Li Vecchi V, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, La Spada E, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV-infected patients. Ann Hepatol 2013;12:740-748.
25. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;160:369-379.
26. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr 2015;68:456-462.
27. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007;47:527-537.
28. Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol 2014;28:23-30.
29. Borgia SM. FibroScan® access in Canada: Time for reform, a call for universal access. Can J Gastroenterol Hepatol 2015;29:221-222.
30. Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, et al. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2013;7:e449-e456.
31. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199-2207.
32. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012;18:716-726.
33. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006;12:801-807.
34. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; doi:10.1016/j.cgh.2015.05.030.
35. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52:612-622.
36. Mosoian A, Hong F, Saiman Y, Rahman A, Branch AD, Roayaie S, et al. HIV infection of Kupffer cells results in dysregulated response to LPS despite effective antiretroviral therapy [Abstract]. Hepatology 2013;58:281A. Abstract 145.
37. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226-233.
38. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014;11:362-371.
39. + T-cell counts. J Infect Dis 2012;206:1568-1576.
40. Kokordelis P, Kramer B, Korner C, Boesecke C, Voigt E, Ingiliz P, et al. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology 2014;59:814-827.
41. Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006;3:e492.
42. Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AET, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006;43:573-580.
43. + T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol 2013;59:427-433.
44. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
45. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013;158:235-245.
46. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-DeltaG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis 2014;209:350-354.
47. Trepo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2014;59:2170-2177.
48. Verma S. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction? J Antimicrob Chemother 2006;58:496-501.
49. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, Tate JP, Williams PL, Seage GR 3rd, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014;58:719-727.
50. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-2568.
51. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713.
52. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55.
53. Loko M-A, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontain H, Bonnard P, et al. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther 2012;17:1335-1343.
54. Sherman KE, Guedj J, Shata MT, et al. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Sci Transl Med 2014;6:246ra98.
55. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008;47:250-257.
56. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV AIDS 2014;9:365-370.
57. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-1239.
58. Naggie SC, C; Saag, M.S.; Yang, J.c. et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 [Abstract]. In: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Abstract 152LB.
59. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015;313:1223-1231.
60. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-1106.
61. Wyles DR, P.; Sulkowski, M.; Dieterich, D.; Luetkemeyer A.; Morgan, T.; Sherman, K.E.; Liu, Z.; Noviello S; Ackerman, P. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study [Abstract]. In: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Abstract 151LB.
62. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-954.
63. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353-361.
64. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312:410-425.
65. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013;8:e68152.
66. Wohl D, Pozniak A, Thompson M, et al. Tenofovir alafenamide (TAF) in a single-tablet regimen in initial HIV-1 therapy [Abstract]. In: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Abstract 113LB.
67. Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, et al. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses 2013;29:665-672.
68. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 2015;64:1314-1326.
69. Hawkins C, Agbaji O, Ugoagwu P, Thio CL, Auwal MM, Ani C, et al. Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. Clin Infect Dis 2013;57:e189-e192.
70. Miailhes P, Pradat P, Chevallier M, Lacombe K, Bailly F, Cotte L, et al. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat 2011;18:61-69.
71. Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596-606.
72. de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-427.
73. Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis 2007;45(Suppl. 4):S313-S317.
74. Rausch DM, Grossman CI, Erbelding EJ. Integrating behavioral and biomedical research in HIV interventions: challenges and opportunities. J Acquir Immune Defic Syndr 2013;63(Suppl. 1):S6-S11.
75. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013;57(Suppl. 2):S56-S61.
76. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat 2012;43:424-432.
77. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56:806-816.
78. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007;18:406-410.
79. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, et al. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med 2012;6:179-185.
80. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl. 2):S39-S45.